Source: GlobeNewswire

Press Release: Cidara : Cidara Therapeutics Hosting Key Opinion Leader Meeting on Rezafungin and Cloudbreak Programs

SAN DIEGO, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will host a Key Opinion Leader (KOL) meeting on its rezafungin and Cloudbreak programs on November 14 in New York City for institutional investors, sell-side analysts, and business development professionals.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Jeffrey Stein's photo - President & CEO of Cidara

President & CEO

Jeffrey Stein

CEO Approval Rating


Cidara develops and commercializes novel anti-infectives and immunotherapies for the treatment of fungal infections. Read more